Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Monday, October 21, 2019 · 499,840,022 Articles · 3+ Million Readers

Adult Malignant Glioma Therapeutics Market to Reach US$ 2,964.5 Mn by 2026, Exhibiting a CAGR of 9.3% | Fortune Business Insights

Key companies covered in the Adult Malignant Glioma Therapeutics Market Research report include Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, Pfizer Inc., AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Novocure.

/EIN News/ -- Pune, Aug. 14, 2019 (GLOBE NEWSWIRE) -- The global Adult Malignant Glioma Therapeutics Market is likely to grow in the coming years due to advancements made in targeted therapy to treat malignant glioma. According to a report published by Fortune Business Insights, titled Adult Malignant Glioma Therapeutics Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 1,459.1 Mn. Fortune Business Insights states that the market is likely to reach US$ 2,964.5 Mn at a CAGR of 9.3% in the forecast period.

According to the World Health Organization (WHO), almost 2,45,000 brain tumor cases are registered every year. Despite advancements in treatment options and awareness regarding prevention of tumor at an early stage, the incidence of brain tumor has been on the rise. With increasing glioma cases and a low survival rate among people diagnosed with glioma, there are several market players focusing solely on the research and development of novel therapeutics to treat adult malignant glioma. The aforementioned factors are driving the global Adult Malignant Glioma Therapeutics Market.


Browse Complete Report Details with Table of Content and Figures:
https://www.fortunebusinessinsights.com/industry-reports/adult-malignant-glioma-therapeutics-market-100572


New Imaging Technique May Help Remove Malignant Tumor Altogether

Researchers have come up with a new imaging technique that may help in eliminating the malignant tumor from the human body, altogether. This imaging method may help surgeons locate the tumor with ease. Researchers have claimed that this technique involves the use of a synthetic version of a molecular compound found in the venom of a scorpion. The method also involves the use of an infra-red (IR) camera along with an imaging reagent tozuleristide (BLZ-100). The primary aim of this method was to determine the boundaries between a healthy tissue and tumor. This helps in retaining the healthy tissue after the surgery and thus increases the efficiency of the overall process. Such discoveries are likely to favour growth of the global Adult Malignant Glioma Therapeutics Market in the forthcoming years.

Blue Earth Announces FDA Clearance for Glioma Drug

In December 2018, Blue Earth announced that it has received FDA clearance for a new drug “Axumin”, which has application in positron emission tomography (PET) imaging for removing tumors. The company announced that Fluciclovin (or Axumin) enables PET imaging that may help detect the precise location of the tumor within the body. Along with precise location, the size and severity of tumor can also be traced. This will massively help in treating the malignant glioma disorder and reduce the overall fatality rate among people diagnosed with this disorder. Thus, the FDA approval will help the company take huge strides towards their aim of developing an efficient malignant glioma treatment method. Blue Earth’s success may have impact on the global Adult Malignant Glioma Therapeutics Market and will lead to growth of the market in the coming years.


Sample PDF   https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/adult-malignant-glioma-therapeutics-market-100572


Some of the leading companies that are operating in the global adult malignant therapeutics market are Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, Pfizer Inc., AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Novocure.

Key Companies Covered

  • Merck & Co., Inc.
  • Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novocure


Speak to Analyst https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/adult-malignant-glioma-therapeutics-market-100572


Table of Content:

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities

  • Key Insights
    • Prevalence of glioma by key countries
    • Overview of technological advancements in the glioma therapy
    • Recent industry developments such as mergers& acquisitions
    • Pipeline Analysis

  • Global Adult Malignant Glioma Therapeutics Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Application
      • Glioblastoma Multiforme
      • Anaplastic Astrocytoma
      • Anaplastic Oligodendroglioma
      • Others
    • Market Analysis, Insights and Forecast – By Type
      • Chemotherapy
      • Radiotherapy
      • Targeted Therapy
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Specialty Clinics
      • Cancer and Radiation Therapy Centers
      • Others
    • Market Analysis, Insights and Forecast – By Country
      • North America
      • Europe
      • Asia Pacific
      • Rest of World
  • Competitive Analysis
  • Strategic Recommendations


Request for Customization:  https://www.fortunebusinessinsights.com/enquiry/customization/adult-malignant-glioma-therapeutics-market-100572

 
Browse Related Reports:

  • Glaucoma Therapeutics Market Size, Share and Global Trend by Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026

  • Cardiovascular Therapeutics Market Size, Share and Global Trend by Drug Class (Anti-Hyperlipidemia, Anti-fibrinolytic, Anti-hypertensive, Others), Disease Type (Cardiac Arrhythmias, Arteriosclerosis, Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Others), Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies), and Forecast till 2026
  • Lung Cancer Therapeutics Market Size, Share and Global Trend by Therapy (Targeted, Therapy, Immunotherapy, Chemotherapy), By Cancer Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026
  • Breast Cancer Therapeutics Market Size, Share and Global Trend by Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Cancer Type (Hormone Receptor, HER2+), and Geography Forecast till 2026


About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. 

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact us:
Fortune Business Insights Pvt. Ltd. 
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245
Email: sales@fortunebusinessinsights.com 
Website: https://www.fortunebusinessinsights.com

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release